Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31562104 | 0.87 | NR1H2 (0.38) | NR1H3NR1H2MAPTNPC1ALDH1A1 | |
| SCHEMBL15723644 | 0.84 | NR1H2 (0.40) | NR1H3NR1H2MAPTNPC1ALDH1A1 | |
| SCHEMBL14555385 | 0.84 | NR1H2 (0.40) | NR1H3NR1H2MAPTNPC1ALDH1A1 | |
| SCHEMBL585207 | 0.80 | NR1H3 (0.33) | NR1H3NR1H2MAPTNPC1ALDH1A1 | |
| SCHEMBL585010 | 0.80 | NR1H3 (0.33) | NR1H3NR1H2MAPTNPC1ALDH1A1 | |
| SCHEMBL432224 | 0.80 | SETD7 (0.40) | NR1H2MAPTMAPK1USP2SMN1; SMN2 | |
| SCHEMBL1197535 | 0.80 | SETD7 (0.40) | NR1H2MAPTMAPK1USP2SMN1; SMN2 | |
| SCHEMBL1197830 | 0.80 | SETD7 (0.40) | NR1H2MAPTMAPK1USP2SMN1; SMN2 | |
| SCHEMBL13932860 | 0.79 | NR1H2 (0.45) | NR1H3NR1H2MAPTNPC1ALDH1A1 | |
| SCHEMBL14639731 | 0.79 | KDM4E (0.34) | ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4436975-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118696050-A | Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-116715671-A | Application of alpha-chromene spiropiperidine compound in preparation of 5-hydroxytryptamine 2C receptor agonist | 苏州大学 | 2023-09-08 | — | — | CN | disclosed |
| WO-2023097233-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885MAPT 4851/4885 |
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, PMP22, NR1H2 | NR1H3 5/4885NR1H2 3/4885MAPT 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.